期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

晚期肾细胞癌18例治疗体会 被引量：4

下载PDF
导出
摘要 肾细胞癌（renal cell carcinoma,RCC）是最常见的肾脏恶性肿瘤,具有多药耐药性,对放化疗均不敏感,25%～30%的患者就诊时已发生转移,行根治性手术后仍有20%～40%的患者出现复发或转移,发生转移者中位生存期（OS）仅8～12个月,5a生存率不足10%[1]。传统以干扰素α和IL-2为基础的免疫治疗总有效率低且存在严重的不良反应[2]。临床试验[2]证实以舒尼替尼为代表的分子靶向药物在治疗转移性RCC方面能够获得较高疾病控制率,延长患者的无进展生存时间,改善晚期转移性RCC患者的生存状况,
作者 孙如坤 乔保平 王利辉 辛航 闫泽晨 王道元
机构地区 郑州大学第一附属医院泌尿外科
出处 《郑州大学学报（医学版）》 CAS 北大核心 2012年第5期733-734,共2页 Journal of Zhengzhou University(Medical Sciences)
关键词 肾细胞癌 肿瘤转移 舒尼替尼 辅助治疗
分类号 R730.51 [医药卫生—肿瘤]
  • 相关文献

参考文献12

  • 1顾六顺.肾肿瘤[M]//吴阶平.吴阶平泌尿外科学.济南:山东科学技术出版社,2009:889.
  • 2Motzcr RJ, Hutson TE, Tomczak P, et al. Sunitinib ver- sus interferon alfa in metastatic renal-cell carcinoma[ J ]. N Engl J Med,2007,356(2) :115.
  • 3Kuhnert F,Tam BY, Sennino B, et al. Soluble receptor-me- diated selective inhibition of VEGFR and PDGFRbeta sig- naling during physiologic and tumor angiogenesis [ J ]. Proc Natl Acad Sci USA,2008,105(29) :10185.
  • 4王利辉,姜华龙(综述),乔保平(审校).舒尼替尼治疗转移性肾细胞癌的研究进展[J].国际泌尿系统杂志,2009,29(2):217-220. 被引量：2
  • 5Motzer R J, Hutson TE,Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma [ J ]. J Clin Oncol,2009,27 (22) :3584.
  • 6Hwang E, Leel H J, Sul CK, et al. Efficacy and safety of sunitinib on metastatic renal cell carcinoma:a single-insti- tution experience [ J ]. Korean J Urol,2010,51 ( 7 ) :450.
  • 7胡骁轶,王国民,郭剑明,林宗明,孙立安,徐志兵,王杭,仓晨.舒尼替尼治疗转移性肾癌的初步评价[J].中华泌尿外科杂志,2010,31(5):300-303. 被引量：11
  • 8李春香,姚欣,杨庆,陈旭升,刁磊.疑难病例析评 第210例 孤立肾局部晚期中央型肾癌-舒尼替尼新辅助治疗-肾部分切除术[J].中华医学杂志,2010,90(26):1866-1868. 被引量：7
  • 9赵菊平,沈周俊,何竑超,祝宇,张荣明,何威,戴军.新辅助疗法在肾细胞癌综合治疗中的探索[J].现代泌尿生殖肿瘤杂志,2011,3(3):132-135. 被引量：5
  • 10Hellenthal N J, Underwood W, Penetrante R, et al. Prospec- tive clinical trial of preoperative sunitinib in patients with renal cell carcinoma[ Jl ~ J Urol,2010,184( 3 ) :859.

二级参考文献59

  • 1Oudard S, George D, Medioni J, et al. Treatment options in renal cell carcinoma: past,present and future. Ann Oncol 2007,18(10) :x25 - x31.
  • 2Garcia JA, Rini BI. Recent progress in the management of advanced renal cell. CA Cancer J Clin 2007,57:112 - 125.
  • 3Kaelin WG Jr. The von Hippel - Lindau tumor suppressor protein and clear cell renal carcinoma. Clin Cancer Res 2007,13:680s - 684s.
  • 4Linehan WM, Rubin JS, Bottaro DP. VHL loss of function and its impact on oncogenic signaling networks in clear cell renal cell carcinoma. Int J Biochem Cell Biol. 2008 Oct 2.
  • 5Christensen JG. A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti - angiogenic and antitumour activities. Ann Oncol 2007,18 (10) : x3 - x10.
  • 6Veeravagu A, Hsu AR, Cai W,et al. Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as anti - angiogenic agents in cancer therapy. Recent Patents Anticancer Drug Discov. 2007,2( 1 ) : 59 -71.
  • 7Ostman A, Heldin CH. PDGF receptors as targets in tumor treatment. Adv Cancer Res. 2007,97:247 -274.
  • 8Kuhnert F,Tam BY,Sennino B, et al. Soluble receptor - mediated selective inhibition of VEGFR and PDGFRbeta signaling during physiologic and tumor angiogenesis. Proc Natl Acad Sci USA, 2008, 105 (29) :10185 -90.
  • 9Houk B, Garrett M, Bello C, et al. Population pharmacokinetics of SU011248 and its primary metabolite SU12662 in oncology patients. Philadelphia,2005 : 14 - 18.
  • 10Pfizer Inc. data on file.

共引文献19

同被引文献76

  • 1万崇华,陈明清,张灿珍,汤学良,孟琼,张晓磬.癌症患者生命质量测定量表EORTC QLQ-C30中文版评介[J].实用肿瘤杂志,2005,20(4):353-355. 被引量：1305
  • 2石明,韩平,曹贵华,魏强,杨宇如.肾癌术后应用α-干扰素的疗效分析[J].华西医学,2006,21(2):288-289. 被引量：6
  • 3Patel PH, Chaganti RS, Motzer RJ. Targeted therapy formetastatic renal cell carcinoma[J]. Br J Cancer, 2006, 94(5):614-619.
  • 4Sukumaran R, Mathews A, Somanathan T, et al. Renal cellcarcinoma metastasizing to adenocarcinoma of esophagogastricjunction: a rare case of tumor-to-tumor metastasis[J]. Indian JPathol Microbiol, 2012, 55(4): 525-527.
  • 5Tan KT, Simpson C, Chandrasekar CR. Hand metastasis: anunusual presentation of renal cell carcinoma[J]. Hand, 2012,7(2): 204-206.
  • 6Macaskill EJ, Bartlett JM, Sabine VS, et al. The mammalian targetof rapamycin inhibitor everolimus (RAD001) in early breastcancer: results of a pre-operative study[J]. Breast Cancer ResTreat, 2011, 128(3): 725-734.
  • 7Bellail AC, Olson JJ, Yang X, et al. A20 ubiquitin ligase-mediatedpolyubiquitination of RIP1 inhibits caspase-8 cleavage andTRAIL-induced apoptosis in glioblastoma[J]. Cancer Discov,2012,2(2): 140-155.
  • 8Lu KV, Chang JP, Parachoniak CA, et al. VEGF inhibits tumorcell invasion and mesenchymal transition through a MET/VEGFR2 complex[J]. Cancer Cell, 2012, 22(1): 21-35.
  • 9Fainaru O, Adini A, Benny O, et al. Dendritic cells supportangiogenesis and promote lesion growth in a murine model ofendometriosis[J]. FASEB J, 2008,22(2): 522-529.
  • 10Hwang E, Lee HJ, Sul CK, et al. Efficacy and safety of sunitinibon metastatic renal cell carcinoma: a single-institutionexperience[J]. Korean J Urol, 2010, 51(7): 450-455.

引证文献4

二级引证文献29

郑州大学学报（医学版）
2012年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部